DGXQUEST DIAGNOSTICS INC
Services-Medical Laboratories
- Revenue
- $11.0B
- 12% YoY
- Operating margin
- 14.1%
- 3.4% YoY
- EBITDA
- $2.1B
- 16% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.2×
- $4.7B net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear190% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear43% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyFired53% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $10.8B | $9.9B | $9.3B | $9.9B | $11.0B | 12% |
| Operating income | $2.4B | $1.4B | $1.3B | $1.3B | $1.6B | 16% |
| Net income | $2.0B | $946M | $854M | $871M | $992M | 14% |
| Operating cash flow | $2.2B | $1.7B | $1.3B | $1.3B | $1.9B | 41% |
| Capex | $403M | $404M | $408M | $425M | $527M | 24% |
| Stock-based comp | $79M | $77M | $77M | $88M | $88M | 0.0% |
| Buybacks | $2.2B | $1.4B | $275M | $151M | $450M | 198% |
| Dividends | $309M | $305M | $314M | $331M | $353M | 6.6% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 5
- Net
- −$3M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 161 | 148 |
| FY2024 | — | — | 137 | 129 |
| FY2023 | — | — | 123 | 126 |
| FY2022 | — | — | 136 | 124 |
| FY2021 | — | — | 148 | 126 |